Key Takeaways
Weed and ADHD: Does Cannabis Help Symptoms?
The research on weed and ADHD points in two directions. In surveys, many adults with ADHD say cannabis calms restlessness and impulsivity in the moment[6][1]. In controlled testing, evidence that it improves attention or cognition is thin: a 30-person trial found no significant benefit on its primary outcome[3].
The most detailed symptom data come from an online survey of 1,738 students that asked how cannabis affected ADHD symptoms, medication side effects and executive function[6]. Among respondents with ADHD who used cannabis to manage their symptoms, nearly 92% said acute use improved their symptoms overall[2].
Ratings for regular use were weaker. About 35% reported overall improvement from chronic use, 14.20% reported worsening, and nearly 37% reported no effect[2]. The reviewers who summarized these results suggest the gap may reflect tolerance to cannabis's psychoactive effects[2].
A study published in 2026, based on a 2023 survey of 900 adults with a documented ADHD diagnosis, found similarly mixed reports[1]. Daily users were more likely than non-daily users to say cannabis eased mental frustration and impulsivity, and also more likely to say it worsened inattention[1].
Self-Reported Acute Effects of Cannabis on ADHD Symptoms
| Symptom | Reported effect | Share of respondents |
|---|---|---|
| Restlessness | Improved | 88.17% |
| Hyperactivity | Improved | 80.47% |
| Mental frustration | Improved | 75.74% |
| Memory | Worsened | 66.86% |
| Inattention | Worsened | 43.20% |
| Inattention | Improved | 39.64% |
Share of college students with ADHD who used cannabis to manage symptoms reporting each acute effect, from the 2022 Stueber and Cuttler survey as summarized by Hernandez and Levin[2][6].
1Self-reported perceptions from a predominantly female student sample, not objective measures of attention or memory[2].
Sources
- •Hernandez and Levin, 2022
- •Stueber and Cuttler, 2022
What the Only Placebo-Controlled Trial Found
The EMA-C trial, published in 2017, randomly assigned 30 adults with ADHD to Sativex, a cannabinoid medication sprayed in the mouth, or to placebo[3]. Its authors noted that a small number of U.S. psychiatrists were prescribing cannabis for ADHD despite no evidence from randomized controlled studies[3].
On the primary outcome, cognitive performance and activity level on the QbTest, the difference between groups was not statistically significant (p=0.16)[3]. Hyperactivity and impulsivity improved nominally (p=0.03), but no result remained significant after adjustment for multiple testing[3].
One serious adverse event (muscular seizures or spasms) and three mild events occurred in the active group, and one serious cardiovascular event occurred in the placebo group[3]. The authors described the results as preliminary rather than definitive and called for further studies[3].
Does Weed Make ADHD Worse?
Cannabis acts on the same functions ADHD already strains. CDC states that use within the past 24 hours affects thinking, attention, memory, coordination and time perception in youth and adults[7].
Use before age 18 may affect how the brain builds connections for attention, memory and learning, and CDC notes those effects may be long-lasting, though more research is needed[7].
In the 2026 adult survey, daily cannabis users with ADHD reported more co-occurring diagnoses than non-daily users: anxiety (70% vs. 48%), depression (54% vs. 35%) and PTSD (30% vs. 14%)[1]. Daily users were also more likely to rate their general health fair or poor (24% vs. 11%)[1].
Those figures come from a one-time survey, so they cannot show whether heavy use led to the other conditions or the reverse[1]. How ADHD overlaps with anxiety and depression on its own is covered in separate posts.
Cannabis use disorder
A condition in which a person is unable to stop using cannabis even though it is causing health and social problems in their life[8]. CDC estimates that about 3 in 10 people who use cannabis have cannabis use disorder, with higher risk among those who start young and use more often[8].
Related Terms
Source: Centers for Disease Control and Prevention
Why People With ADHD Use Cannabis More Often
Use is common in this group. In the 2026 survey, 75% of adults with diagnosed ADHD had ever used cannabis, 41% had used it in the past 30 days, and 42% of those who had ever used it said they had used it to manage ADHD symptoms[1].
The gap appears early. The Multimodal Treatment Study of ADHD (MTA) followed children diagnosed at a mean age of 8.5 to a mean age of 25[9]. In adulthood, weekly marijuana use was 32.8% in the ADHD group vs. 21.3% among classmates without ADHD[9].
Genetic studies point the same way. A 2020 Mendelian randomization analysis of genome-wide data on 53,293 people for ADHD and 32,330 for cannabis use supported ADHD as a cause of lifetime cannabis use, with an odds ratio of 7.9[10]. The same analysis estimated a genetic correlation of 0.29 between the two traits[10].
Background on inherited ADHD risk is in Is ADHD genetic?, which covers twin and genome studies.
Researchers call this the self-medication theory: some people with ADHD may use cannabis to dampen symptoms[3]. A 2022 review lists untreated or undertreated ADHD symptoms, pain, anxiety and sleep problems as reported motives[2]. The reward-system explanation is covered in ADHD and dopamine.
People with ADHD who have had cannabis use disorder at some point in life (14-study meta-analysis)
That is 2.85 times the general-population risk. Estimates varied widely across studies, with a prediction interval of 12.4% to 48.8%.
"lifetime and current prevalence rates of CUD in ADHD populations were 26.9% and 19.2%"
How Often ADHD and Cannabis Use Disorder Overlap
A 2024 meta-analysis of 14 studies estimated that 26.9% of people with ADHD had a lifetime diagnosis of cannabis use disorder and 19.2% had a current one[4]. Those rates are 2.85 and 2.91 times the general-population risk[4].
Frequency of use tracks with risk. In the 2026 adult survey, 62% of daily cannabis users with ADHD had cannabis use disorder, compared with 38% of non-daily users[1]. CDC likewise reports higher risk among people who start in adolescence and use more often[8].
U.S. rates for all addictions are on the substance use disorder page, and the factors linked to them are reviewed in substance use disorder risk factors.
Cannabis Outcomes in ADHD Studies
| Measure | ADHD group | Comparison | Study |
|---|---|---|---|
| Lifetime cannabis use disorder | 26.9% | 2.85x general-population risk | Meta-analysis, 2024 |
| Current cannabis use disorder | 19.2% | 2.91x general-population risk | Meta-analysis, 2024 |
| Weekly marijuana use, mean age 25 | 32.8% | 21.3% (no ADHD) | MTA cohort, 2018 |
| Early substance use in adolescence | 57.9% | 41.9% (no ADHD) | MTA cohort, 2018 |
| Cannabis use disorder among cannabis users with ADHD | 62% (daily users) | 38% (non-daily users) | Adult survey, 2026 |
Cannabis use and cannabis use disorder in people with ADHD compared with reference groups, from a 14-study meta-analysis, the MTA cohort and a 2023 U.S. adult survey[4][9][1].
1MTA children had DSM-IV combined-type ADHD and were compared with 258 classmates without ADHD[9].
2Survey groups are adults with a documented ADHD diagnosis, split by past-month cannabis use frequency[1].
Sources
- •Froude et al., 2024
- •Molina et al., 2018
- •Ryan et al., 2026
Weed and ADHD Medication
Students with ADHD in the 2022 survey said cannabis eased most of their medication side effects, such as irritability and anxiety[6]. That is self-report; none of the studies cited here tested the safety of combining cannabis with stimulants under controlled conditions.
A frequent question is whether ADHD medication changes later substance use. Among 2,993,887 adolescent and adult patients in 2005 to 2014 commercial insurance claims, months on ADHD medication were associated with 35% lower odds of substance-related emergency visits for men and 31% lower odds for women[11].
The MTA follow-up of 579 children found no evidence that stimulant treatment raised or lowered later marijuana or other substance use into early adulthood[12]. Drug classes and trial results are compared in ADHD meds and ADHD treatment for adults.
Is Cannabis or CBD an Approved ADHD Treatment?
No. FDA has not approved a marketing application for cannabis to treat any disease or condition[5]. It has approved one cannabis-derived drug, Epidiolex (cannabidiol, or CBD), for seizures linked to Lennox-Gastaut or Dravet syndrome, and three synthetic cannabis-related drugs, Marinol, Syndros and Cesamet, for uses such as chemotherapy-related nausea[5].
FDA states that no other cannabis, cannabis-derived or CBD product on the market has its approval[5]. CBD products sold for ADHD are therefore unapproved, and the only placebo-controlled cannabinoid trial in adults with ADHD tested Sativex rather than CBD alone[3].
The 2022 review advises clinicians to ask why patients use cannabis, such as for sleep, anxiety or pain, because those symptoms may respond to other drug or behavioral treatments[2].
Frequently Asked Questions
Sources & References
- Ryan JE, Herens A, Fruchtman M, et al. Cannabis use in a community-based sample of adults diagnosed with ADHD: prevalence, impact on symptoms, and stimulant side effects. Journal of Attention Disorders. Published 2026. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/40874736/ [Link]
- Hernandez M, Levin FR. Attention-deficit hyperactivity disorder and therapeutic cannabis use motives. Psychiatric Clinics of North America. Published 2022. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11032069/ [Link]
- Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. European Neuropsychopharmacology. Published 2017. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/28576350/ [Link]
- Froude AM, Fawcett EJ, Coles A, et al. The prevalence of cannabis use disorder in attention-deficit hyperactivity disorder: a clinical epidemiological meta-analysis. Journal of Psychiatric Research. Published 2024. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/38452637/ [Link]
- U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. U.S. Food and Drug Administration. Published 2023. Accessed October 2026. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process [Link]
- Stueber A, Cuttler C. Self-reported effects of cannabis on ADHD symptoms, ADHD medication side effects, and ADHD-related executive dysfunction. Journal of Attention Disorders. Published 2022. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/34632827/ [Link]
- Centers for Disease Control and Prevention. Cannabis and Brain Health. Centers for Disease Control and Prevention. Published 2024. Accessed October 2026. https://www.cdc.gov/cannabis/health-effects/brain-health.html [Link]
- Centers for Disease Control and Prevention. Understanding Your Risk for Cannabis Use Disorder. Centers for Disease Control and Prevention. Published 2024. Accessed October 2026. https://www.cdc.gov/cannabis/health-effects/cannabis-use-disorder.html [Link]
- Molina BSG, Howard AL, Swanson JM, et al. Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study. Journal of Child Psychology and Psychiatry. Published 2018. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/29315559/ [Link]
- Soler Artigas M, Sánchez-Mora C, Rovira P, et al. Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. Molecular Psychiatry. Published 2020. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/30610198/ [Link]
- Quinn PD, Chang Z, Hur K, et al. ADHD medication and substance-related problems. American Journal of Psychiatry. Published 2017. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/28659039/ [Link]
- Molina BSG, Kennedy TM, Howard AL, et al. Association between stimulant treatment and substance use through adolescence into early adulthood. JAMA Psychiatry. Published 2023. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/37405756/ [Link]